



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2021 #9

March 19, 2021

## INSIDE:

COVID-19 Convalescent Plasma Updates .....	3
Upcoming ABC Webinars – Don't Miss Out! .....	3
March SMT Journal Club Webinar .....	4
ABC Member Value Report Now Available ...	4
PEOPLE .....	5
WORD IN WASHINGTON .....	5
MEMBER NEWS .....	6
GLOBAL NEWS .....	7
COMPANY NEWS .....	8
CALENDAR .....	9
POSITIONS .....	10

## Sanquin Announces Changes to MSM Deferrals in a Move to an Individual Risk-based Approach

This week Sanquin, the national blood provider for the Netherlands, informed the Minister of Health, Welfare[,] and Sport that the blood bank is revising its deferral policies for men who have sex with other men (MSM). The revision will happen in two phases beginning in September 2021.

Sanquin will begin allowing blood donations from MSM “in lasting monogamous relationships.” According to an announcement from the organization, “a further extension will be prepared to allow MSM outside of a relationship to be admitted as a blood donor by the end of 2022, without the current deferral [period] of four months. In so doing, Sanquin sets equal treatment as the starting point for its admission policy.”

Sanquin Chief Executive Officer Tjark Tjin-a-Tsoi further explained the policy revision by stating in the announcement that, “[e]qual treatment is an important topic for Sanquin. Since 2015, we have been taking measures to allow more MSM as donors, based on our own and external scientific research. Now we are adapting our risk group approach to a more individually focused assessment of risks to blood safety.” This will allow more MSM to become blood donors than under the current policy (4 months deferral after the last MSM contact).”

The current risk approach was described as “still defer[ring] groups for blood donation if there is a strongly increased risk of infection. Due to the combination with the reliable blood tests, this approach results in very few transfusion-related infections from chronic or even fatal diseases. This group approach is based on empirical scientific data, which show a relative larger number of blood-borne infections within the group of Dutch MSM as compared to those who have heterosexual contact only.”

The organization explained the change to an individual risk-based approach as “[b]ased on Sanquin's studies, combined with the highly sensitive blood tests, it is expected that these two steps can be taken safely. Patients must continue to rely on a safe blood supply,” added Daphne Thijssen, director of the blood bank, in the announcement.

Sanquin further explained that the organization had “actively investigated the possibility of broadening its donor policy” and “decided to broaden our horizons and ask independent ethical and legal philosophers [for their views] on [the matter.]”

(continued on page 2)

Sanquin Announces Move to Individual Risk-based MSM Approach (continued from page 1)

This [new] ethical-philosophical approach is unique, no country has addressed the issue in this way. This contributed to our intention to broaden the MSM policy. This means that the Netherlands remains at the forefront of both donation policy by MSM worldwide and in the field of transfusion safety.”

The second phase will specifically ask about behavior with a higher risk of contracting blood-borne infections. “For the next stage, a practical solution must be found to accept MSM without a steady partner as a blood donor, without compromising the safety of blood transfusions. Sanquin expects to have more on this development at the end of next year.” Ms. Thijssen added, “[i]t seems simple, but it’s not. As with the first step, we investigate how to quickly and accurately find higher risk behavior, based on a set of targeted and validated questions. How detailed do the questions need to go? When does a donor become uncomfortable? Do the questions cover the risks sufficiently? We use this time to research and prepare for this.”

In December of 2020, the United Kingdom (UK) [announced](#) upcoming changes to its blood donation deferral criteria that will impact men who have sex with other men (MSM). In a move that UK officials called “landmark,” the new guidelines will be adopted in the summer of 2021 and apply a more individual risk-based approach removing the current three-month deferral for MSM. Specifically, the new policy will allow “donors who have had one sexual partner and who have been with their sexual partner for more than three months” to be eligible to donate. Additionally, “all donors will complete the same donor health check prior to donation, regardless of gender or sexuality, recogni[z]ing that all donors, including heterosexual men and women, have potential to carry infections.”

(Source: Sanquin Announcement, 3/15/21) 💧



The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2021 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

**America’s Blood Centers**

Chief Executive Officer: Kate Fry  
 Chief Medical Officer: Rita Reik  
 Editor: Mack Benton  
 Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$390**

Send subscription queries to [memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
 America’s Blood Centers  
 1717 K St. NW, Suite 900, Washington, DC 20006  
 Phone: (202) 393-5725  
 Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



## COVID-19 Convalescent Plasma Updates

*\*\*Please note that data compilation in the chart below runs through March 7<sup>th</sup>. Moving forward, data compilation will be redeveloped now that the industry has moved to collecting high titer CCP exclusively.\*\**

### Convalescent Plasma: Industry Collections and Distributions



### Get ready. Get set. Go. New Integrated Platelet Bacterial Samplers for LVDS

It's time to get ready for the new FDA guidelines\* issued to control bacterial risk in platelets. The first step is creating SOPs that include your large-volume delayed sampling (LVDS) strategy.

Let us help you prepare with information on integrated sampling kits — available for use with the Trima Accel® Automated Blood Collection System Version 7 — as well as an example SOP.

The FDA deadline is almost here — so let's get started. Contact your Terumo Blood and Cell Technologies sales associate today.



**TERUMO** BLOOD AND CELL TECHNOLOGIES

©2021 Terumo BCT, Inc. | BC-TRIM-00525  
\*Download the guidelines at [fda.gov/media/123448/download](https://www.fda.gov/media/123448/download)

### Upcoming ABC Webinars – Don't Miss Out!

- **ABC SMT Journal Club Webinar** – March 31<sup>st</sup> from 1 – 2 p.m. (ET). The articles to be discussed on the webinar are [available](#) to ABC members on the Medical Issues Listserv. Additional details including login information to join the webinar are also available to ABC members in MCN 21-028. Please contact [us](#) with questions or to receive a copy of the MCN.



**America's Blood Centers®**  
It's About *Life.*

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.*

### March SMT Journal Club Webinar

The America's Blood Centers (ABC) Scientific, Medical, and Technical (SMT) Journal Club Webinar on March 31<sup>st</sup> at 1 p.m. EDT will feature the articles below:

- The effect of red blood cell transfusion on fatigability after hospital discharge (*Blood Advances*);
- Fecal blood loss: A quantitative method of evaluating hemostasis in patients with thrombocytopenia (*Transfusion*); and
- HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men (*Transfusion*).

Additional details including login information to join the webinar are now available to ABC members in MCN 21-028. Please contact [us](#) with questions or to receive a copy of the MCN.

(Source: MCN 21-028, 3/17/21)

### ABC Member Value Report Now Available

ABC has published the fiscal year 2021 (April 1<sup>st</sup>, 2020 – March 31<sup>st</sup>, 2021) member value [report](#). It provides a snapshot of the work completed over the previous year on behalf of member blood centers. ABC encourages member blood center to review the report and actively engage with us by providing [feedback](#). Also, please share the report with members of your staff and board of directors to communicate the continued value of your ABC membership. Thank you for all you did to contribute to an outstanding year.

(Source: ABC Member Value [Report](#), 3/15/21) 💧

### Cellphire Request for Apheresis Platelet Units

Cellphire, Inc. is a biomedical research organization located in Rockville, M.D. Currently, Cellphire is conducting two separate Phase II clinical trials. Both trials require a weekly supply of FDA licensed, leukocyte reduced, Apheresis Platelet Units (APU). For one trial, IND 17156, the APUs, once received by Cellphire, are pooled, filtered using a process of Tangential Flow Filtration (TFF) which reduces the excess plasma, then a cryoprotectant solution is added to the pooled APU, aliquoted to glass vials, and then lyophilized. The lyophilized product is termed "Thrombosomes". For the other trial, IND 14047, the APU have an added requirement. They must be licensed, irradiated and leukocyte reduced. These APUs are plasma reduced, mixed with 6% percent DMSO, and then frozen and stored in an Ultra-Low Freezer at ≤-65C. These DMSO frozen platelets are termed "CPP". Information on each of these clinical trials may be found on [Clinicaltrials.gov](https://clinicaltrials.gov). More information available [here](#).



## PEOPLE

**Harpreet Sandhu, MBA**, chief executive officer of Stanford Blood Center, has been [honored](#) by the *Silicon Valley Business Journal* with a “C-suite Award.” She is one of 14 business executives recognized for their leadership during the COVID-19 pandemic and received the award on March 4<sup>th</sup> following her organization being one of the first in the U.S. to implement a convalescent plasma donation program according to the publication. “I’m extremely proud of our team,” said Ms. Sandhu to the *Silicon Valley Business Journal*. “We were able to get convalescent plasma units out regionally, but also nationally...It’s really allowed us to do what we do best, but do it in yet an even more innovative way.”



(Source: *Silicon Valley Business Journal*, “[C-suite Awards](#),” 2/26/21)



**Beau R. Webber, PhD** has been [announced](#) as the 26<sup>th</sup> recipient of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative Scott Murphy Memorial Award Lectureship. He currently serves as assistant professor in the Department of Pediatrics at the University of Minnesota (Twin Cities, Minn.). Dr. Webber will deliver a lecture on “The bench-to-bedside development of a novel, first-in-human CRISPR/Cas9 engineered T cell therapy for metastatic gastrointestinal cancer” during the 61<sup>st</sup> Meeting of BEST, which will be held virtually on April 16<sup>th</sup>. A list of prior award recipients and their presentation titles can be found on the BEST [website](#).

(Source: BEST [News Release](#), 3/6/21) 💧

## WORD IN WASHINGTON

**[Xavier Becerra, JD](#)** has been confirmed by the U.S. Senate as the 25<sup>th</sup> secretary of the U.S. Department of Health and Human Services (HHS). He will lead the agency after previously serving as a 12-term member of Congress and as attorney general for the state of California. During his Congressional tenure, Mr. Becerra was a “Ranking Member of the Ways And Means Subcommittee on Social Security and member of the Ways and Means Subcommittee on Health. He spent 10 years in the leadership of the House of Representatives, both serving as the Vice Chairman and Chairman of the House Democratic Caucus. As a senior member on the Committee on Ways And Means and as a member of the House, he worked to develop the Children’s Health Insurance Program, the Affordable Care Act, reduce health disparities in Medicare and Medicaid, and protect Social Security and disability insurance.”

(Source: HHS [Announcement](#), 3/19/21)

**HHS recently [announced](#) the appointments of several staff members.** “President Biden’s team at HHS is growing quickly and continues to work tirelessly to end the COVID pandemic and address our many health challenges,” said HHS Chief of Staff Sean McCluskie in an agency news release. “Our appointees will work hand-in-hand with our dedicated team of career officials throughout HHS to protect and expand quality, affordable care to all Americans.” Among the appointments are Sarah Newman Boateng, who will serve as Chief of Staff to the Officer of the Assistant Secretary for Health (OASH). She most recently held the role of executive deputy secretary at the Pennsylvania Department of Health. Prior to that, Ms. Boateng served as the special assistant to the Physician General at the Department of Health and the director of Public Affairs at Planned Parenthood Keystone. The agency also announced that Adam Beckman is serving as Special Advisor to the Surgeon General. He most recently served as a special advisor to the 19th Surgeon General of the U.S. and previously held roles spanning nonprofit, startup, and policy organizations focused on delivering better, more affordable healthcare and responding to the COVID-19 pandemic.

(Source: HHS [News Release](#), 3/2/21) 💧



## MEMBER NEWS

**New York Blood Center (NYBC)** recently had an [analysis](#) published in [Science Magazine](#). The authors, Christopher Hillyer, MD, president and chief executive officer at NYBC, and Larry Luchsinger, PhD, head of the Laboratory of Stem Cell Regenerative Research and director of the NYBC iPSC Program, share their research in a letter in the publication that all three vaccines, approved for use by the U.S. Food and Drug Administration (FDA), “create enough antibodies to fight the virus variants.” Dr. Luchsinger stated in an announcement from NYBC, “[o]ur analysis finds that there is more than enough evidence to support that the vaccines will work against mutated forms of COVID-19. It has been incredible to see the science community come together and create these three vaccines in just under a year’s time. Given the increasing number of vaccinations each day and their effectiveness against COVID-19, we are very hopeful that the pandemic will soon be behind us.” Also, according to the announcement, NYBC continues to work on developing “two novel SARS-CoV-2 vaccine candidates that are currently in pre-clinical studies, conducting vaccines trials, and investigating biomarkers that may determine individuals at risk for severe disease.”

(New York Blood Center [Announcement](#), 3/17/21)

**Cascade Regional Blood Services (CRBS)** is [celebrating](#) its 75<sup>th</sup> anniversary. Founded in 1946, CRBS serves the Tacoma, Federal Way, Puyallup, and Gig Harbor communities in Washington state. “The longevity of CRBS is a testament to the generosity of folks who live in our communities,” said Candy Morrison, director of Communications and Community Relations at CRBS, to SouthSoundTalk.com. “It is the dedicated donors throughout the decades that have selflessly given their time and lifesaving blood products to patients in our community hospitals. People helping people. It’s what we do and who we are.”



(Source: SouthSoundTalk.com, [Cascade Regional Blood Services Celebrates 75 Years as a Leading Community Blood Center](#), 3/17/21)

**LifeServe Blood Center** held its annual “Blue Blood Drive” earlier this year, a partnership with Iowa’s Concerns for Police Survivors (C.O.P.S) organization. The annual event promotes the importance of blood donation while celebrating the work of local law enforcement professionals and providing their loved ones and community supporters an opportunity to give back. This year’s event turned into a week-long promotion that resulted in a friendly competition among law enforcement and first responders leading to more than 3,500 appointments to donate, five times the amount of the previous year. “This [is] a great partnership to show our connection with first responders in our community and also to give this group of heroes a dedicated time for them to show their support for the volunteer blood donor program., said LifeServe Director of Public Relations and Marketing Danielle West in an announcement to the *ABC Newsletter*. “In their line of work, they see firsthand the importance and need of a strong and stable blood supply and see the value of rolling up their sleeve to give blood.” Building on the success of the “Blue Blood Drive,” LifeServe has scheduled additional drives with local firefighters and emergency medical services organizations throughout the community.

(Source: LifeServe Blood Center Announcement, 3/16/21) 💧





## GLOBAL NEWS

**The United Kingdom (UK) recently [lifted](#) its ban on UK-sourced plasma.** The decision comes in the wake of a recommendation from scientific experts at the independent Commission on Human Medicines (CHM) who deemed UK-sourced plasma as safe for the manufacturing of immunoglobulins following a “comprehensive review.” The ban had been in place since 1998 amid concerns over variant Creutzfeldt Jakob Disease (vCJD). “Following expert advice, I am pleased we are now able to lift this ban to help thousands of NHS patients access these potentially life-saving treatments as quickly as possible,” said Health Minister Lord Bothell in a UK Department of Health and Social Care (DHSC) News Release. “The move will also help England become self-sufficient and we will not have to rely only on imports from other countries, ensuring every NHS patient can always access the treatments they need. The safety of NHS patients remains our absolute priority and we have put in place robust precautionary measures to ensure every batch is safe.” NHS Blood and Transplant (NHSBT), the national blood provider for England and transplant services for the UK, Chief Executive Betsy Bassis added in an organization [news release](#), “[t]his is an exciting opportunity for the UK to reduce its dependence on the US for critical plasma-derived medicines on which so many patients depend. We are so pleased that our donors’ gifts will now be able to save and improve even more lives in the years ahead. This is an exciting day for donors and patients alike.” UK DHSC officials explained, “[u]p until now, the UK has depended on imports of blood plasma from other countries, mainly the U.S., to manufacture these treatments. Due to a large rise in global demand for immunoglobulins, both plasma and these treatments have experienced ongoing pressures on supply in the UK and around the world in recent years. The impact of the COVID-19 pandemic has also meant a significant drop in plasma donations from the U.S., further increasing pressures on supply. The lifting of the ban will bolster the supply chain and improve the self-sufficiency of the UK in producing its own treatments. The government will also introduce a new condition to ensure UK plasma is used first for UK patients and not exported to meet contracts elsewhere.”

**NHSBT also [announced](#) this week that it stopped the collection of COVID-19 convalescent plasma on March 18<sup>th</sup> following a request from DHSC.** According to a statement from the organization, the decision “follows the completed analysis of trial results which showed no overall benefit for people in hospital with coronavirus, and a decision not to resource a third trial into plasma use early in the disease. We will now begin to transition a significant part of our network over to collecting plasma for lifesaving medicines... We will start collecting plasma donations for medicines at some cent[ers] early in April... The third convalescent plasma trial that was being explored, of early plasma use in people at higher risk, will not be resourced. The Therapeutics Taskforce said that it would not be beneficial to carry out additional trials at this time, based on the trial results and declining patient numbers. Plasma held in stock will be repurposed where possible for fresh frozen plasma, fractionation, or other treatments. We will continue to support the wider pandemic response through a range of progra[ms]... Now, we can support the UK’s need for immunoglobulin medicines amidst global supply pressures. NHSBT already collects plasma as a byproduct of whole blood donations but a dedicated plasmapheresis progra[m] will greatly increase NHSBT’s ability to provide plasma at volume. This will play an important part in reducing the UK’s reliance on international suppliers... We are incredibly grateful to everyone who has donated. Donation will be altruistic, for the benefit of the NHS. [We] will collect on a cost-recovery basis.”

(Sources: UK Department of Health and Social Care [News Release](#), 2/25/21; NHSBT [News Release](#), 2/25/21; NHSBT [Statement](#), 3/18/21)

**The World Health Organization [published](#) a report on Human T-lymphotropic virus type I (HTLV-I).** It includes prevention and control strategies such as:

- HTLV-I screening in prenatal care and blood safety panels;

(continued on page 8)

GLOBAL NEWS (continued from page 7)

- “[t]esting approaches and strategies for HTLV-1 detection that are appropriate to the setting and purpose should be developed and incorporated into health sector diagnostic algorithms and referral protocols;
- [s]pecific research and assessments to define the risk of HTLV-1 transmission associated with the duration of breastfeeding are needed to develop public health progra[ms] for the elimination of mother to child transmission; [and]
- innovations in viral disease control will help improve the management of HTLV-1 infection. These include better technologies for testing and treatment, future vaccine development, instituting stand-ard approaches for measuring disease burden and more widespread adoption of ongoing monitoring and surveillance, including instituting new digital tools.”

The full report is [available](#) on the WHO website.

(Source: WHO [Announcement](#), 3/3/21) ◆

**COMPANY NEWS**

**Grifols** [announced](#) the “fostering” of a scientific journal devoted to the science of plasma. The publication, titled *Plasmatology*, debuted on March 9<sup>th</sup> and is “edited independently, with its editorial committee and director answering only to the prestigious publisher SAGE Publications , a longtime publisher of respected scientific journals covering different medical disciplines, life sciences, engineering, the humanities, and other areas.” According to a news release, the international journal will be both open access and peer reviewed. “[W]e’re celebrating the creation of *Plasmatology* and we believe without a doubt it will accelerate the knowledge and research of proprietary plasma therapeutics,” said Grifols Co-Chief Executive Officer (CEO) Víctor Grifols Deu in the news release. “In addition it’s particularly gratifying that the birth of the publication coincides with the 70th anniversary of the development of plasmapheresis by my uncle Josep Antoni Grifols i Lucas. The company’s commitment to research and scientific publishing forms part of his legacy,” added Grifols Co-CEO Raimon Grifols Roura.

(Source: Grifols [News Release](#), 3/8/21)

**Grifols** also recently [acquired](#) GigaGen, a U.S. biopharmaceutical company focused on the development of the “the world’s first recombinant polyclonal immunoglobulin.” According to a company news release, Grifols now fully controls GigaGen with the purchase of the additional 56 percent of the remaining shares that were not part of a 2017 transaction between the two organizations. “We are further strengthening our innovation strategy by investing in solid projects, such as Alkahest and now GigaGen, with the aim of helping patients live longer and better lives,” said Grifols Co-CEO Víctor Grifols Deu in the news release. “Projects like these support our long-term vision and have high potential to bolster our corporate growth and business fundamentals.” José Terencio, vice-president of Innovation at Grifols, added, “[t]he progress that GigaGen is making to boost the next generation of antibody drugs, including the world’s first recombinant polyclonal immunoglobulin, will enhance Grifols’ innovation efforts, aiming disease management beyond plasma-derived therapies.”

(Source: Grifols [News Release](#), 3/9/21)

The National Institutes of Health (NIH) [announced](#) that a phase I clinical trial of two **Regeneron** monoclonal antibody (mAb) candidates to treat Middle East respiratory syndrome (MERS) “were well tolerated and generally safe when administered simultaneously to healthy adults.” According to a NIH news release, “The trial was the first to test the experimental antibodies in people...[T]he study enrolled 48 healthy adults, 36

(continued on page 9)



COMPANY NEWS (continued from page 8)

of whom received the mAbs. All volunteers were followed for 121 days after receiving mAbs (or placebo) by intravenous infusion. No serious adverse events occurred... Together, the findings from the clinical trial and the preclinical mouse studies “demonstrate the potential efficacy and utility of monoclonal antibody therapy for the prevention or treatment of MERS-CoV and lays the groundwork for the development of spike-targeted mAb therapies for other infectious disease threats, including SARS-CoV-2.”

(Source: NIH [News Release](#), 2/23/21) 💧

### ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

## CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org) or by fax to (202) 899-2621. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

### 2021

April 15. **FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meeting (Virtual)**. More details available [here](#).

May 4-6. **IPFA/PEI 27<sup>th</sup> International Workshop on Surveillance and Screening of Blood-borne Pathogens (Virtual)**. More details available [here](#).

May 12-13. **Elevate Your Donor Journey: ADRP Master Class in Finding Your XFactor (Virtual)**. More details available [here](#).

May 21-22. **64<sup>th</sup> Annual California Blood Bank Society Annual Meeting (Virtual)**. More details available [here](#).

Aug. 4. **ABC Medical Directors Workshop, Cleveland, Ohio**. More details coming [soon](#).

Aug. 5-6. **ABC Summer Summit, Cleveland, Ohio**. More details coming [soon](#).

Aug. 17-19. **2021 ADRP Conference, Kansas City, Mo**. More details coming [soon](#).

Sept. 15-17. **4<sup>th</sup> European Conference on Donor Health and Management, Hamburg, Germany**. More details available [here](#).

Oct. 16-19. **AABB Annual Meeting**. More details available [here](#). 💧

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Vice President, Donor Sourcing (Collections) (Anywhere, USA).** Vitalant is a nonprofit organization that collects blood from volunteer donors and provides blood, blood products and services across the United States. Under minimal direction, this position is responsible for Donor Sourcing policies and procedures ensuring effective and efficient processes for the Blood Services Division. Requirements: Bachelor's degree required. Master's preferred. Knowledge of large system operations management including fiscal policies, human resource management, and strategic planning required. Knowledge of federal, state, and local regulations that affect business operations required. Ten years of related experience required. To include: Six years senior leadership experience. Prior executive experience and knowledge of collections process preferred. Apply [here](#). EOE

**Operations Coordinator of Mobile Staging.** OUR WORK IS LIFE-SAVING...YOURS CAN BE TOO! Join our team as an Operations Coordinator of Mobile

Staging! You will be responsible for overseeing all aspects of Bedford/Waco Mobile Staging and Centralized Scheduling. This includes development and implementation of all operational activities with emphasis on continuous process and improvement. Responsible for overseeing the preparation of payroll, supplies, equipment, vans, coaches, and finalization of mobile drive schedules needed for daily mobile operations. Responsible for overall management of mobile staging and scheduling technicians. If you have at least three years of Management experience and want to be a part of making a difference please apply [here](#) on our company website to be considered. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities (EEO) to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing.

**Donor Recruitment Manager (Blood Assurance, Nashville area).** Supervise and lead our Account Managers field recruitment efforts that build new and existing business in the assigned communities served by Blood Assurance. Assist in developing long-term community business partnerships, and coordinating internally with all leadership levels to support or expand Blood Assurance recruitment efforts. Qualified candidates will have a bachelor's degree in business, marketing, or related field. Advanced communication skills, organizational skills,

teamwork, customer service, follow up, networking, negotiation, and judgment. Also requires initiative, creative problem solving, conflict resolution, staff management and development. The hiring process begins with submitting an online employment application at [www.bloodassurance.org](http://www.bloodassurance.org). Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

**Operations Manager (Blood Assurance, Nashville area).** Manage our collection efforts in the greater Nashville, TN and surrounding areas. This position will be responsible for operational oversight of collection services for multiple collection teams in an assigned territory. Supervises staff in coordination with other department leaders and ensures compliance with all Standard Operating Procedures, FDA and AABB regulations. Monitors performance in the areas of productivity, proficiency, and customer service. Bachelor's degree required with some prior supervisory/management experience in blood banking is required. The hiring process with submitting an online employment application at [www.bloodassurance.org](http://www.bloodassurance.org). Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

**Medical Technologist or MLT (Blood Assurance, Nashville area).** Position in our Nashville lab location to perform basic to complex serologic patient testing and interpret result to determine donor-recipient compatibility. May consult and communicate with staff at other medical facilities, to resolve serologic problems and provide special units to transfusion recipients. Qualified candidates must have current State of Tennessee Medical Laboratory license and AS/BS Degree. Strong blood banking skills preferred. The hiring process begins with submitting an online employment application at [www.bloodassurance.org](http://www.bloodassurance.org). Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

**Specialist in Blood Banking (SBB) Certificate Program.** The LifeSouth Specialist in Blood Banking (SBB) certificate program, an independent educational program offering training in all aspects of blood banking and transfusion medicine, is accepting applications for the 2021-2022 class. Starting date is 06/14/2021. [Application](#) deadline has been extended to 04/30/2021. Click [here](#) for additional information.

(continued on page 11)

## POSITIONS (continued from page 10)

**Assistant Manager of Component Production (Carter BloodCare).** Functions: The Assistant Manager of Component Production will assist the Manager in all aspects of coordination of Component Production manufacturing functions. You will oversee daily operations, direct supervision of the production team, interviews, adhere to the fiscal budget, and any task to ensure efficient workflow with strong judgment and decisiveness. You will also collaborate with other blood centers on projects and corporate initiatives. Education: MLT ASCP or equivalent. Experience: Two years' supervisory experience in blood banking production, OR 5 years' supervisory experience in a government-regulated production environment, OR combination of education and experience. Two years' experience with computer blood banking/inventory management software. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities (EEO) to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing. Click [here](#) to apply.

**Medical Affairs Counselor (Scottsdale, AZ).** Vitalant is a nonprofit organization that collects blood from volunteer donors and provides blood, blood products and services across the United States. Under minimal supervision, this position is responsible for verbally counseling donors, physicians, and customers on the medical significance of infectious disease markers and responding to questions and concerns. Bachelor's degree or equivalent combination of education and experience required. Extensive working knowledge of infectious diseases preferred. RN license or Certification as a Medical Technologist by a recognized certifying agency preferred. Three years' experience in a healthcare environment required. To include: Experience in patient and/or donor education/counseling/communication. Please apply [here](#). EOE

**Phlebotomist/Collections Instructor.** Carter BloodCare is hiring an Instructor to our team in Bedford, Texas. The Instructor position is responsible for the training and continuing education of the Collection Services staff in all procedures involved in the allogeneic and special donation collection process. This includes but is not limited to medical history, donor lookup, phlebotomy, quality control, CPR, basic apheresis, and a minimum of one apheresis technology. This position is also responsible for

ensuring that trainees receive adequate clinical experience, safely performing all required skills and successfully completing competency testing. They plan for and guide the learning process to help students achieve objectives required within the allotted time. They must have adequate transportation to travel. Please click [here](#) to apply. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing.

OneBlood has exciting career opportunities available in the incredible state of Florida! Join our life saving mission in one of the following roles: **Reference Lab Manager (Ft. Lauderdale, FL).** Valid and current Florida Clinical Laboratory Supervisor license in Immunohematology or Blood Banking and SBB certification required. Bachelor's degree in medical technology or related field with five (5) or more years' experience; prior management experience essential. **Compatibility Testing Lab Supervisor (Tallahassee, FL - \$5k Bonus Eligible).** Bachelor's degree in medical technology, biological science, or related field and three plus years in a clinical laboratory, preferably in blood banking. Requires a current Florida Technologist license in Immunohematology or Blood Banking; FL Supervisor License preferred. **Medical Technologist (Tallahassee, FL - \$5k Bonus Eligible).** A valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking is required. Prior blood banking experience preferred. Multiple shifts available. **Therapeutics Apheresis RN (Ft. Lauderdale, FL - \$5k Bonus Eligible).** Current and valid Florida RN license, current BLS CPR certification, and a valid and clear driver's license is required. Flexibility in scheduling needed to meet the needs of the department; travel within the tri-county market in the South Florida area is required. OneBlood offers competitive benefits, including excellent shift differential pay for night and weekend schedules, Paid Time Off, Student Loan Repayment Program, a FREE medical coverage option, 403(b) Retirement Plan, company-paid annual CEU training & CE Broker account and MORE! To apply visit our OneBlood careers website at [www.oneblood.org/careers](http://www.oneblood.org/careers). 💧